Evidence map›Paper›PMID 26432923›Full record

ArticleTranslational research : the journal of laboratory and clinical medicine2015

Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis.

Jun Tashiro, Sharon J Elliot, David J Gerth, Xiaomei Xia, Simone Pereira-Simon, Rhea Choi, Paola Catanuto, Shahriar Shahzeidi, Rebecca L Toonkel, Rahil H Shah and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational research : the journal of laboratory and clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03137199 (A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma), which is not on this map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03137199 phase1terminatednot on this mapstarted 2017, after this paper: background citation

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma

TypeinterventionalSponsorMarilyn GlassbergRan2017 to 2020Enrolled3ConditionsAsthmaArmshMSCs
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jun TashiroDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Sharon J ElliotDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
David J GerthDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Xiaomei XiaDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Simone Pereira-SimonDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Rhea ChoiDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Paola CatanutoDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Shahriar ShahzeidiDivision of Pediatric Pulmonology, Department of Pediatrics, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Rebecca L ToonkelDepartment of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, Fla.
Rahil H ShahDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla.
Fadi El SalemDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.
Marilyn K GlassbergDepartment of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla; Division of Pediatric Pulmonology, Department of Pediatrics, Leonard M. Miller School of Medicine, University of Miami, Miami, Fla. Electronic address: mglassbe@med.miami.edu.
University of Miami · USFlorida International University · USIcahn School of Medicine at Mount Sinai · US

Funding

Idiopathic Pulmonary Fibrosis Clinical Research NetworkU10HL080413 · NHLBI · DUKE UNIVERSITY · PI ANSTROM, KEVIN J · 2005 to 2013
$22.6M
ESTROGEN DEFICIENCY AND RENAL DISEASE IN AGING WOMENR01AG017170 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ELLIOT, SHARON J · 1999 to 2012
$4.6M
NHLBI NIH HHS 5U10HL080413NHLBI NIH HHS U10 HL080413NIA NIH HHS R01 AG017170
6 · The paper itself

Abstract

The observation that pulmonary inflammatory lesions and bleomycin (BLM)-induced pulmonary fibrosis spontaneously resolve in young mice, whereas remaining irreversible in aged mice suggests that impairment of pulmonary regeneration and repair is associated with aging. Because mesenchymal stem cells (MSCs) may promote repair after injury, we postulated that differences in MSCs from aged mice may underlie postinjury fibrosis in aging. The potential for young-donor MSCs to inhibit BLM-induced pulmonary fibrosis in aged male mice (>22 months) has not been studied. Adipose-derived MSCs (ASCs) from young (4 months) and old (22 months) male mice were infused 1 day after intratracheal BLM administration. At 21-day sacrifice, aged BLM mice demonstrated lung fibrosis by Ashcroft score, collagen content, and α(v)-integrin messenger RNA (mRNA) expression. Lung tissue from aged BLM mice receiving young ASCs exhibited decreased fibrosis, matrix metalloproteinase (MMP)-2 activity, oxidative stress, and markers of apoptosis vs BLM controls. Lung mRNA expression of tumor necrosis factor-alpha was also decreased in aged BLM mice receiving young-donor ASCs vs BLM controls. In contrast, old-donor ASC treatment in aged BLM mice did not reduce fibrosis and related markers. On examination of the cells, young-donor ASCs had decreased mRNA expression of MMP-2, insulin-like growth factor (IGF) receptor, and protein kinase B (AKT) activation compared with old-donor ASCs. These results show that the BLM-induced pulmonary fibrosis in aged mice could be blocked by young-donor ASCs and that the mechanisms involve changes in collagen turnover and markers of inflammation.

Indexed as

Age FactorsMesenchymal Stem Cell TransplantationAdipose TissueAnimalsBiomarkersBleomycinDisease Models, AnimalEnzyme ActivationIn Situ Nick-End LabelingMaleMatrix Metalloproteinase 2Mesenchymal Stem CellsMiceMice, Inbred C57BLProto-Oncogene Proteins c-aktPulmonary FibrosisBiomarkersBleomycinMatrix Metalloproteinase 2Proto-Oncogene Proteins c-akt

Identifiers

PMID26432923
PMCPMC4922649
OpenAlexW1946126158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.